Litigation involving US Patent 8377884

8377884

Cases

Active

2 closed

Filed

2025

Top venue

ITC

1 case

BioMarin Pharmaceutical Inc. v. Ascendis Pharma, Inc. et al.

settled/dismissed

Docket:: 337-TA-1447
Court:: U.S. International Trade Commission (Section 337, 19 U.S.C. §1337)
Filed:: 2025-04-02

Patents:8377884 RE48267

π BioMarin Pharmaceutical Inc.Δ Ascendis Pharma, Inc.Δ Ascendis Pharma A/S Δ Ascendis Pharma Growth Disorders A/S Δ Wacker Biotech GmbH Δ Bachem AG

ITC Section 337 investigation titled Certain Drug Products Containing C-Type Natriuretic Peptide Variants, and Components Thereof, brought by BioMarin against Ascendis entities and suppliers regarding TransCon CNP / navepegritide. The asserted patent was U.S. Reissue Patent No. RE48,267; US 8,377,884 was relied on by Ascendis as prior-art Exhibit 32, not asserted. Resolved by a global settlement announced August 30–31, 2026, with the investigation to be dismissed.

Ascendis Pharma A/S v. BioMarin Pharmaceutical Inc.

settled

Docket:: 4:25-cv-05696
Court:: U.S. District Court for the Northern District of California
Terminated:: 2026-08-30

Patents:8377884

π Ascendis Pharma A/S Δ BioMarin Pharmaceutical Inc.

Declaratory-judgment/safe-harbor action by Ascendis Pharma A/S against BioMarin involving §271(e)(1) and a forum dispute with the parallel ITC action. US 8,377,884 was cited in BioMarin's filings as Exhibit 32 in connection with Ascendis's ITC prior-art/protest arguments concerning RE'267, not as an asserted patent. Resolved by the August 30, 2026 global settlement.